Evidence map›Paper›PMID 27215501›Full record

ArticleRespiratory medicine2016

A bundled care approach to patients with idiopathic pulmonary fibrosis improves transplant-free survival.

Tejaswini Kulkarni, John Willoughby, Maria Del Pilar Acosta Lara, Young-Il Kim, Rekha Ramachandran, C Bruce Alexander, Tracy Luckhardt, Victor J Thannickal, Joao A de Andrade

Abstract read
In one paragraph

Article in Respiratory medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Identifying outcome domains to establish a core outcome set for progressive pulmonary fibrosis: a scoping review.European respiratory review : an official journal of the European Respiratory Society · 2025
    Article
  2. Observational
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tejaswini KulkarniDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, 1900 University Blvd., Tinsley Harrison Tower, Suite 422, Birmingham, AL 35294, United States; Birmingham VA Medical Center, 700 South 19th Street, 6th Floor, Rm 6318, Birmingham, AL 35233, United States.
John WilloughbyDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, 1900 University Blvd., Tinsley Harrison Tower, Suite 422, Birmingham, AL 35294, United States.
Maria Del Pilar Acosta LaraDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, 1900 University Blvd., Tinsley Harrison Tower, Suite 422, Birmingham, AL 35294, United States; Birmingham VA Medical Center, 700 South 19th Street, 6th Floor, Rm 6318, Birmingham, AL 35233, United States.
Young-Il KimDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, 1900 University Blvd., Tinsley Harrison Tower, Suite 422, Birmingham, AL 35294, United States; Division of Preventive Medicine, Department of Medicine, University of Alabama at Birmingham, Medical Towers, Suite 621, 1720 2nd Ave South, Birmingham, AL 35294, United States; Birmingham VA Medical Center, 700 South 19th Street, 6th Floor, Rm 6318, Birmingham, AL 35233, United States.
Rekha RamachandranDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, 1900 University Blvd., Tinsley Harrison Tower, Suite 422, Birmingham, AL 35294, United States; Division of Preventive Medicine, Department of Medicine, University of Alabama at Birmingham, Medical Towers, Suite 621, 1720 2nd Ave South, Birmingham, AL 35294, United States.
C Bruce AlexanderDepartment of Pathology, University of Alabama at Birmingham, P210 West Pavilion, 619 South 19th Street, Birmingham, AL 35233, United States.
Tracy LuckhardtDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, 1900 University Blvd., Tinsley Harrison Tower, Suite 422, Birmingham, AL 35294, United States.
Victor J ThannickalDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, 1900 University Blvd., Tinsley Harrison Tower, Suite 422, Birmingham, AL 35294, United States; Birmingham VA Medical Center, 700 South 19th Street, 6th Floor, Rm 6318, Birmingham, AL 35233, United States.
Joao A de AndradeDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, 1900 University Blvd., Tinsley Harrison Tower, Suite 422, Birmingham, AL 35294, United States; Birmingham VA Medical Center, 700 South 19th Street, 6th Floor, Rm 6318, Birmingham, AL 35233, United States. Electronic address: joao@uab.edu.

Funding

Therapeutic Targeting of the Myofibroblast in Fibrotic Lung DiseaseP01HL114470 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI THANNICKAL, VICTOR J. · 2013 to 2022
$17.8M
NHLBI NIH HHS P01 HL114470
6 · The paper itself

Abstract

backgroundIdiopathic pulmonary fibrosis (IPF) is a chronic lung disease with poor prognosis and limited therapeutic options. The 2011 ATS/ERS/JRS/ALAT consensus statement provided a number of recommendations for the management of IPF patients. The primary objective of this study was to determine if "bundling" these recommendations in the management of patients with IPF impacts clinical outcomes.

methodsWe conducted a single center, retrospective cohort study of 284 patients diagnosed with IPF. The proposed bundle of care (BOC) components were: (1) visits to a specialized interstitial lung diseases clinic with evaluation of pulmonary function tests at least twice yearly; (2) referral to pulmonary rehabilitation yearly; (3) timed walk test yearly; (4) echocardiogram yearly; and (5) gastroesophageal reflux therapy. Each component of the BOC was given a score of "1" per year of follow up, and the average sum of the scores (ranging from 0 to 5) was determined for the entire period of follow-up (BOCS), as well as during the first year of follow-up (BOCY1). The primary outcome measure was transplant-free survival.

resultsAge, gender, smoking status, BMI, %FVC, %DLCO did not differ between levels of BOCS and BOCY1. Lowest BOCS (≤1) was associated with a lower transplant-free survival independent of age and %FVC compared to patients with the highest BOCS (>4) (HR 2.274, CI 1.12-4.64, p = 0.024). Lower BOCY1 was associated with a higher risk for transplant or death independent of age and %FVC in comparison to patients with highest BOCY1 (≤1 vs. >4, HR 2.23, p = 0.014; >1 to 2 vs. >4, HR 1.87, p = 0.011; >2 to 3 vs. >4, HR 1.72, p = 0.019).

conclusionIPF patients with higher BOC scores had improved transplant-free survival. Prospective studies are needed to confirm these findings and determine the best strategies for the management of patients with IPF.

Indexed as

Survival RateAgedEchocardiographyFemaleGastroesophageal RefluxGuideline AdherenceHumansIdiopathic Pulmonary FibrosisMaleMiddle AgedOutcome Assessment, Health CarePatient Care BundlesRespiratory Function TestsRetrospective StudiesTransplantsWalk TestBundled careIdiopathic pulmonary fibrosisTransplant-free survival

Identifiers

PMID27215501
PMCPMC4879776

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.